vinblastine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
vinca alkaloids 2823 865-21-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • vinblastine
  • vincaleukoblastine
  • vincaleucoblastin
  • vincaleucoblastine
  • vinblastin
  • vinblastine sulfate
  • vinblastine sulphate
Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
  • Molecular weight: 810.99
  • Formula: C46H58N4O9
  • CLOGP: 4.30
  • LIPINSKI: 3
  • HAC: 13
  • HDO: 3
  • TPSA: 154.10
  • ALOGS: -4.68
  • ROTB: 10
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 10 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability) 0 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 28 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 3.10 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.14 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 67 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 2.927 High 0.89
caco2-efflux Caco-2 efflux ratio (BA/AB) 149.279 High 0.89
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 0.762 10^-6 cm/s High 0.89
dh-clint Dog hepatocyte intrinsic clearance 6.902 uL/min/10^6 cells High 0.89
dppb Dog plasma protein binding (% unbound) 14.600 % High 0.89
fcs-ppb Fetal calf serum protein binding (% unbound) 27.450 % High 0.89
herg hERG pIC50 4.599 pIC50 High 0.89
hh-clint Human hepatocyte intrinsic clearance 3.436 uL/min/10^6 cells High 0.89
hlm-clint Human liver microsomal intrinsic clearance 59.293 uL/min/mg protein High 0.89
hppb Human plasma protein binding (% unbound) 22.500 % High 0.89
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 13.552 High 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 28.510 High 0.89
mh-clint Mouse hepatocyte intrinsic clearance 13.996 High 0.89
mppb Mouse plasma protein binding (% unbound) 13.570 High 0.89
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 35.892 High 0.89
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 1 High 1
pppb Pig plasma protein binding (% unbound) 23.110 % High 0.89
rat-kpuu-brain Rat brain Kpuu 0.007 % High 1
rh-clint Rat hepatocyte intrinsic clearance 3.963 uL/min/10^6 cells High 0.89
rh-fuinc Rat hepatocyte fraction unbound in incubation 34.730 % High 0.89
rppb Rat plasma protein binding (% unbound) 14.040 % High 0.89
solubility-dd Solubility at pH 7.4 in DMSO 628.058 uM High 0.89

Approvals:

DateAgencyCompanyOrphan
Nov. 5, 1965 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 310.45 28.05 176 6700 158173 90463398
Neutropenia 255.98 28.05 177 6699 224727 90396844
Neuropathy peripheral 123.92 28.05 94 6782 136876 90484695
Pulmonary toxicity 113.89 28.05 40 6836 11491 90610080
Disease progression 108.65 28.05 92 6784 156523 90465048
Pancytopenia 107.57 28.05 82 6794 120181 90501390
Second primary malignancy 98.68 28.05 35 6841 10343 90611228
Malignant neoplasm progression 84.98 28.05 68 6808 106802 90514769
Interstitial lung disease 83.90 28.05 59 6817 76346 90545225
Off label use 68.16 28.05 210 6666 1102042 89519529
Abdominal compartment syndrome 68.05 28.05 15 6861 768 90620803
Pneumocystis jirovecii pneumonia 67.77 28.05 33 6843 21583 90599988
Basal ganglion degeneration 60.35 28.05 12 6864 370 90621201
Myelodysplastic syndrome 59.85 28.05 30 6846 20873 90600698
Posterior reversible encephalopathy syndrome 57.96 28.05 30 6846 22309 90599262
Tissue infiltration 55.76 28.05 13 6863 857 90620714
Refractory anaemia with an excess of blasts 52.74 28.05 11 6865 432 90621139
Anaesthesia 52.23 28.05 11 6865 453 90621118
Congestive cardiomyopathy 52.17 28.05 20 6856 7334 90614237
Acute myeloid leukaemia 51.49 28.05 27 6849 20613 90600958
Dysaesthesia 51 28.05 18 6858 5237 90616334
Toxic neuropathy 50.41 28.05 11 6865 537 90621034
Uterine enlargement 50.10 28.05 13 6863 1335 90620236
Ileus 48.11 28.05 24 6852 16522 90605049
Leukaemia 48.07 28.05 17 6859 4975 90616596
Product use in unapproved indication 48.02 28.05 89 6787 336147 90285424
Febrile bone marrow aplasia 46.73 28.05 20 6856 9718 90611853
Sepsis 45.68 28.05 62 6814 179752 90441819
Psychogenic seizure 44.92 28.05 13 6863 2003 90619568
Polyneuropathy 44.57 28.05 24 6852 19317 90602254
Inguinal hernia 44.41 28.05 13 6863 2085 90619486
Lymphadenopathy 42.60 28.05 32 6844 45743 90575828
Pyrexia 39.78 28.05 125 6751 660360 89961211
Hypochromic anaemia 39.64 28.05 12 6864 2159 90619412
Premature baby 38.77 28.05 24 6852 25053 90596518
Neurological decompensation 37.86 28.05 13 6863 3488 90618083
Cytomegalovirus viraemia 37.79 28.05 16 6860 7570 90614001
Monoplegia 37.24 28.05 13 6863 3661 90617910
Respiratory failure 36.58 28.05 45 6831 118373 90503198
Colitis 36.40 28.05 35 6841 69907 90551664
Premature menopause 36.08 28.05 10 6866 1319 90620252
Pleuroparenchymal fibroelastosis 35.62 28.05 7 6869 203 90621368
Mucosal inflammation 34.15 28.05 31 6845 57594 90563977
Hyperpyrexia 33.96 28.05 13 6863 4748 90616823
Cardiomyopathy 32.93 28.05 20 6856 20186 90601385
Intervertebral disc disorder 32.23 28.05 13 6863 5447 90616124
Hepatotoxicity 31.85 28.05 27 6849 45815 90575756
Meningitis streptococcal 31.82 28.05 6 6870 139 90621432
Vanishing bile duct syndrome 31.25 28.05 9 6867 1363 90620208
Pseudohyponatraemia 30.01 28.05 5 6871 55 90621516
Foetal exposure during pregnancy 29.22 28.05 25 6851 42950 90578621
Exposure during pregnancy 28.97 28.05 59 6817 238351 90383220
Acute respiratory distress syndrome 28.81 28.05 21 6855 28665 90592906
Genital ulceration 28.79 28.05 8 6868 1065 90620506
Cardiotoxicity 28.69 28.05 15 6861 11374 90610197
Pericarditis constrictive 28.56 28.05 7 6869 571 90621000
Bone pain 28.50 28.05 29 6847 61954 90559617
Neoplasm progression 28.47 28.05 25 6851 44461 90577110
Infusion site joint movement impairment 28.40 28.05 4 6872 12 90621559
Myelosuppression 28.22 28.05 27 6849 53564 90568007

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 313.31 24.05 263 7512 185440 42428120
Second primary malignancy 231.93 24.05 81 7694 9494 42604066
Neutropenia 160.31 24.05 189 7586 199242 42414318
Acute myeloid leukaemia 148.11 24.05 75 7700 22181 42591379
Azoospermia 102.81 24.05 23 7752 511 42613049
Disease progression 92.44 24.05 122 7653 143534 42470026
Off label use 84.77 24.05 281 7494 638054 41975506
Neuropathy peripheral 83.95 24.05 98 7677 101755 42511805
Cardiotoxicity 83.42 24.05 36 7739 7409 42606151
Chronic myeloid leukaemia 75.67 24.05 25 7750 2467 42611093
Endocarditis noninfective 72.12 24.05 14 7761 150 42613410
Product use in unapproved indication 71.91 24.05 124 7651 184332 42429228
Malignant neoplasm progression 69.55 24.05 92 7683 108308 42505252
Myositis 65.11 24.05 38 7737 14828 42598732
Neutrophil count decreased 60.69 24.05 66 7709 63349 42550211
Pulmonary toxicity 59.97 24.05 30 7745 8625 42604935
Cytomegalovirus chorioretinitis 53.97 24.05 23 7752 4588 42608972
Pneumocystis jirovecii pneumonia 53.43 24.05 41 7734 25140 42588420
Testicular disorder 47.64 24.05 14 7761 938 42612622
Autoimmune neutropenia 45.47 24.05 11 7764 347 42613213
Interstitial lung disease 44.83 24.05 63 7712 78399 42535161
Neoplasm progression 44.27 24.05 39 7736 28961 42584599
Pancytopenia 40.45 24.05 75 7700 117668 42495892
Bone marrow failure 39.87 24.05 39 7736 33054 42580506
Myelodysplastic syndrome 39.63 24.05 33 7742 22712 42590848
Asthenospermia 36.77 24.05 7 7768 67 42613493
Mucosal inflammation 34.88 24.05 44 7731 49330 42564230
Germ cell cancer metastatic 34.11 24.05 5 7770 6 42613554
Optic glioma 33.99 24.05 6 7769 36 42613524
Treatment failure 33.87 24.05 49 7726 62575 42550985
Cardiac dysfunction 33.42 24.05 15 7760 3384 42610176
Pyrexia 33.37 24.05 151 7624 393891 42219669
Haematotoxicity 32.74 24.05 22 7753 10963 42602597
Polyneuropathy 32.35 24.05 27 7748 18634 42594926
Cytopenia 31.76 24.05 26 7749 17471 42596089
Pneumonia salmonella 30.28 24.05 6 7769 72 42613488
Vasogenic cerebral oedema 29.88 24.05 10 7765 1026 42612534
Peripheral sensory neuropathy 29.65 24.05 19 7756 8743 42604817
Guillain-Barre syndrome 27.72 24.05 17 7758 7246 42606314
Skin toxicity 26.72 24.05 16 7759 6533 42607027
Peripheral nerve injury 26.44 24.05 7 7768 319 42613241
Ichthyosis 26.10 24.05 6 7769 151 42613409
Spindle cell sarcoma 25.99 24.05 6 7769 154 42613406
Peripheral motor neuropathy 25.52 24.05 11 7764 2253 42611307
Cryptococcal fungaemia 25.25 24.05 6 7769 175 42613385
Blindness 25.10 24.05 23 7752 17955 42595605
Inclusion body myositis 24.59 24.05 5 7770 69 42613491
Pneumonitis 24.55 24.05 34 7741 41684 42571876

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 551.01 23.32 388 13072 316379 110259460
Neutropenia 369.80 23.32 329 13131 374291 110201548
Second primary malignancy 334.80 23.32 113 13347 17955 110557884
Disease progression 221.87 23.32 205 13255 243829 110332010
Acute myeloid leukaemia 212.06 23.32 100 13360 38010 110537829
Neuropathy peripheral 177.32 23.32 158 13302 179119 110396720
Pulmonary toxicity 162.01 23.32 66 13394 17680 110558159
Malignant neoplasm progression 157.23 23.32 146 13314 174421 110401418
Product use in unapproved indication 122.07 23.32 205 13255 447172 110128667
Pancytopenia 120.94 23.32 138 13322 209475 110366364
Interstitial lung disease 118.62 23.32 113 13347 139221 110436618
Off label use 118.01 23.32 424 13036 1499761 109076078
Pneumocystis jirovecii pneumonia 117.33 23.32 70 13390 42665 110533174
Myelodysplastic syndrome 101.86 23.32 61 13399 37423 110538416
Chronic myeloid leukaemia 100.38 23.32 32 13428 4241 110571598
Cardiotoxicity 80.86 23.32 40 13420 16841 110558998
Neutrophil count decreased 78.95 23.32 85 13375 120856 110454983
Endocarditis noninfective 69.10 23.32 14 13446 291 110575548
Mucosal inflammation 68.84 23.32 71 13389 96070 110479769
Pyrexia 66.85 23.32 250 13210 898015 109677824
Cytopenia 64.15 23.32 42 13418 30074 110545765
Neoplasm progression 59.94 23.32 55 13405 64540 110511299
Myelitis 59.10 23.32 20 13440 3193 110572646
Haematotoxicity 53.89 23.32 33 13427 21049 110554790
Sepsis 53.50 23.32 121 13339 327225 110248614
Myositis 53.46 23.32 38 13422 31078 110544761
Basal ganglion degeneration 53.11 23.32 12 13448 424 110575415
Posterior reversible encephalopathy syndrome 52.82 23.32 39 13421 33822 110542017
Polyneuropathy 52.49 23.32 38 13422 31974 110543865
Abdominal compartment syndrome 51.81 23.32 16 13444 1911 110573928
Pleuroparenchymal fibroelastosis 49.74 23.32 11 13449 352 110575487
Uterine enlargement 48.05 23.32 13 13447 972 110574867
Tissue infiltration 47.31 23.32 13 13447 1030 110574809
Cytomegalovirus chorioretinitis 46.80 23.32 21 13439 7107 110568732
Tooth malformation 46.36 23.32 9 13451 149 110575690
Congestive cardiomyopathy 46.20 23.32 26 13434 14193 110561646
Disease recurrence 45.52 23.32 46 13414 60738 110515101
Anaesthesia 44.17 23.32 11 13449 593 110575246
Bone marrow failure 43.72 23.32 44 13416 57804 110518035
Therapy partial responder 43.32 23.32 36 13424 37025 110538814
Myelosuppression 42.71 23.32 55 13405 94285 110481554
Asthenospermia 41.94 23.32 7 13453 46 110575793
Pneumonitis 41.72 23.32 49 13411 76482 110499357
Dysaesthesia 41.25 23.32 19 13441 6828 110569011
Refractory anaemia with an excess of blasts 40.48 23.32 11 13449 836 110575003
Ileus paralytic 39.60 23.32 22 13438 11715 110564124
Leukaemia 39.56 23.32 19 13441 7499 110568340
Progressive multifocal leukoencephalopathy 39.50 23.32 29 13431 24927 110550912
Thrombocytopenia 39.27 23.32 112 13348 348773 110227066
Ileus 38.33 23.32 31 13429 30698 110545141
Respiratory failure 37.86 23.32 82 13378 215250 110360589
Autoimmune neutropenia 37.59 23.32 10 13450 701 110575138
Toxic neuropathy 37.41 23.32 11 13449 1112 110574727
Joint swelling 37.10 23.32 5 13455 442840 110132999
Psychogenic seizure 36.83 23.32 13 13447 2351 110573488
Germ cell cancer metastatic 36.13 23.32 5 13455 6 110575833
Guillain-Barre syndrome 35.87 23.32 20 13440 10724 110565115
Oligohydramnios 33.54 23.32 14 13446 3980 110571859
Lymphadenopathy 33.36 23.32 40 13420 63795 110512044
Bronchopulmonary aspergillosis 32.82 23.32 28 13432 29835 110546004
Pneumonia salmonella 31.98 23.32 6 13454 82 110575757
Renal salt-wasting syndrome 30.91 23.32 9 13451 879 110574960
Weight increased 30.24 23.32 7 13453 419637 110156202
Nasopharyngitis 29.59 23.32 6 13454 394355 110181484
Hypochromic anaemia 29.53 23.32 12 13448 3189 110572650
Anxiety 28.65 23.32 4 13456 345074 110230765
Left ventricular dysfunction 27.83 23.32 23 13437 23470 110552369
Monoplegia 27.64 23.32 13 13447 4896 110570943
Haemophagocytic lymphohistiocytosis 27.58 23.32 26 13434 31533 110544306
Rash 27.32 23.32 36 13424 820928 109754911
Hepatotoxicity 27.19 23.32 36 13424 63364 110512475
Arthralgia 27.18 23.32 33 13427 779599 109796240
Swelling 27.05 23.32 5 13455 351036 110224803
Febrile bone marrow aplasia 26.97 23.32 20 13440 17445 110558394
Ichthyosis 26.67 23.32 6 13454 208 110575631
Septic shock 26.55 23.32 59 13401 157469 110418370
Infusion site joint movement impairment 26.51 23.32 4 13456 12 110575827
Optic glioma 26.47 23.32 5 13455 71 110575768
Vanishing bile duct syndrome 26.25 23.32 11 13449 3157 110572682
Bacteraemia 26.25 23.32 29 13431 42361 110533478
Cardiomyopathy 26.25 23.32 26 13434 33499 110542340
Intervertebral disc disorder 26.21 23.32 13 13447 5499 110570340
Malignant transformation 26.12 23.32 9 13451 1516 110574323
Meningoencephalitis amoebic 25.88 23.32 6 13454 238 110575601
Inclusion body myositis 25.86 23.32 5 13455 81 110575758
Pneumocystis jirovecii infection 25.85 23.32 12 13448 4388 110571451
Pruritus 25.60 23.32 20 13440 581540 109994299
Spindle cell sarcoma 25.41 23.32 6 13454 258 110575581
Ejection fraction decreased 25.37 23.32 28 13432 40852 110534987
Drug ineffective for unapproved indication 25.14 23.32 45 13415 102793 110473046
Acanthamoeba infection 24.75 23.32 7 13453 616 110575223
Hypothyroidism 24.74 23.32 37 13423 72862 110502977
Cryptococcal fungaemia 24.55 23.32 6 13454 299 110575540
Infusion related reaction 24.39 23.32 8 13452 381154 110194685
Pain 24.22 23.32 50 13410 954905 109620934
Hyperpyrexia 24.19 23.32 14 13446 8055 110567784
Infusion site ulcer 24.14 23.32 4 13456 25 110575814
Brain oedema 24.13 23.32 24 13436 31074 110544765
Oropharyngeal squamous cell carcinoma 23.83 23.32 6 13454 338 110575501
Muscle spasms 23.62 23.32 3 13457 278154 110297685
Urticaria 23.61 23.32 5 13455 318852 110256987
Neurological decompensation 23.49 23.32 13 13447 6870 110568969
Bone pain 23.46 23.32 34 13426 65099 110510740
Depression 23.44 23.32 5 13455 317330 110258509
Peripheral sensory neuropathy 23.32 23.32 18 13442 16662 110559177

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01CA01 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS
Vinca alkaloids and analogues
FDA CS M0022674 Vinca Alkaloids
MeSH PA D000970 Antineoplastic Agents
MeSH PA D000972 Antineoplastic Agents, Phytogenic
MeSH PA D050256 Antimitotic Agents
MeSH PA D050257 Tubulin Modulators
FDA EPC N0000175612 Vinca Alkaloid
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35705 immunosuppressive agent
CHEBI has role CHEBI:61951 microtubule-destabilising agent
CHEBI has role CHEBI:76924 plant metabolite

Related Drugs by ATC class:

L01CA Vinca alkaloids and analogues 5 drugs
vincristinevindesinevinfluninevinorelbinevintafolide

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Kaposi's sarcoma indication 109385007
Hodgkin's disease indication 118599009
Non-Hodgkin's lymphoma indication 118601006
Langerhans cell histiocytosis, disseminated indication 118614007
Mycosis fungoides indication 118618005
Malignant tumor of testis indication 363449006 DOID:2998
Carcinoma of female breast indication 447782002
Gestational trophoblastic neoplasia indication 609519004 DOID:3590
Metastatic Breast Carcinoma indication
Non-small cell lung cancer off-label use 254637007 DOID:3908
Malignant tumor of head and/or neck off-label use 255056009
Malignant tumor of urinary bladder off-label use 399326009 DOID:11054
Neuroblastoma off-label use 432328008 DOID:769
Ovarian Germ Cell Tumor Carcinoma off-label use
Mycosis contraindication 3218000 DOID:1564
Hyperbilirubinemia contraindication 14783006 DOID:2741
Disorder of lung contraindication 19829001 DOID:850
Viral disease contraindication 34014006 DOID:934
Depressive disorder contraindication 35489007
Hyperuricemia contraindication 35885006 DOID:1920
Hepatic failure contraindication 59927004
Bacterial infectious disease contraindication 87628006
Impaired wound healing contraindication 271618001
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Peripheral nerve disease contraindication 302226006
Neutropenic disorder contraindication 303011007 DOID:1227
Bone marrow depression contraindication 307762000
Breastfeeding (mother) contraindication 413712001
Myocardial ischemia contraindication 414795007 DOID:3393
Protozoal Infection contraindication
Severe Leukopenia contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.32 acidic
pKa2 13.81 acidic
pKa3 7.54 Basic
pKa4 6.84 Basic
pKa5 6.11 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Tubulin beta Tumour-associated antigen INHIBITOR IC50 9 IUPHAR SCIENTIFIC LITERATURE
Multidrug resistance protein 1 Transporter Ki 7 CHEMBL
Canalicular multispecific organic anion transporter 1 Transporter WOMBAT-PK
Multidrug resistance-associated protein 7 Transporter WOMBAT-PK
Thromboxane-A synthase Enzyme IC50 5.73 DRUG MATRIX
Multidrug resistance-associated protein 1 Transporter WOMBAT-PK
Proteasome subunit beta type-1 Enzyme IC50 5.37 CHEMBL
Proteasome subunit beta type-2 Enzyme IC50 5.31 CHEMBL
Proteasome subunit beta type-5 Enzyme IC50 5.34 CHEMBL
Amine oxidase [flavin-containing] B Enzyme Ki 4.11 CHEMBL
Arachidonate 15-lipoxygenase Enzyme IC50 5.30 DRUG MATRIX

External reference:

IDSource
4019970 VUID
N0000148055 NUI
D01068 KEGG_DRUG
143-67-9 SECONDARY_CAS_RN
4017457 VANDF
4019970 VANDF
C0042670 UMLSCUI
CHEBI:27375 CHEBI
VLB PDB_CHEM_ID
CHEMBL159 ChEMBL_ID
CHEMBL378544 ChEMBL_ID
D014747 MESH_DESCRIPTOR_UI
DB00570 DRUGBANK_ID
6851 IUPHAR_LIGAND_ID
1101 INN_ID
5V9KLZ54CY UNII
13342 PUBCHEM_CID
11198 RXNORM
5674 MMSL
7980 MMSL
856 MMSL
d00400 MMSL
002654 NDDF
002655 NDDF
12436009 SNOMEDCT_US
387051009 SNOMEDCT_US
387115000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Vinblastine Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 63323-278 INJECTION 1 mg INTRAVENOUS ANDA 22 sections